C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01)
Patent
CA 2227402
A diagnostic method and kit for assessing the risks of smoking and CYP2A6-related cancers in an individual. Specifically, there is disclosed a diagnostic method and kit which facilitates identification of individuals who: (i) are at risk of becoming smokers, (ii) smoke more or less if they become dependent, and/or (iii) may be at relatively higher or lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of procarcinogens. The diagnosis involves analyzing (via a genotype or phenotype assay) a DNA-containing bodily sample from the individual for the presence of a mutant allele of human cytochrome P450 enzyme CYP2A6. If at least one mutant allele of human cytochrome P450 enzyme CYP2A6 is present in the individual, that individual: has a lower risk of becoming a smoker, smokes less if he/she becomes dependent and is at relatively lower risk for cancer due to both decreased smoke exposure and decreased enzyme-mediated activation of tobacco smoke procarcinogens. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described.
Sellers Edward M.
Tyndale Rachel F.
Bereskin & Parr
Nicogen Inc.
Sellers Edward M.
Tyndale Rachel F.
LandOfFree
Cyp2a6 diagnostic methods and treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyp2a6 diagnostic methods and treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyp2a6 diagnostic methods and treatments will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1443859